Scarica l'app Stockscreener
2.27
0.89%
0.02
Dopo l'orario di chiusura:
2.26
-0.01
-0.44%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.25
Aprire:
$2.25
Volume 24 ore:
580.15K
Relative Volume:
0.73
Capitalizzazione di mercato:
$184.46M
Reddito:
Utile/perdita netta:
$-78.15M
Rapporto P/E:
-2.6478
EPS:
-0.8573
Flusso di cassa netto:
$-68.89M
1 W Prestazione:
-6.20%
1M Prestazione:
-16.24%
6M Prestazione:
-31.21%
1 anno Prestazione:
-17.15%
Intervallo 1D:
$2.2101
$2.349
Intervallo di 1 settimana:
$2.2101
$2.58
Portata 52W:
$1.35
$4.60
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Nome
Eledon Pharmaceuticals Inc
Settore
Industria
Telefono
949-238-8090
Indirizzo
19800 MACARTHUR BLVD., IRVINE
Compare ELDN vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
2.27 | 184.46M | 0 | -78.15M | -68.89M | -0.8573 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-18 | Ripresa | H.C. Wainwright | Buy |
| 2025-01-28 | Iniziato | Guggenheim | Buy |
| 2022-05-13 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-03-23 | Iniziato | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Borsa (ELDN) Ultime notizie
A kidney transplant study will spotlight what patients report on Oct. 23 - Stock Titan
Eledon Pharmaceuticals (Nasdaq:ELDN)Stock Analysis - Simply Wall Street
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society - markets.businessinsider.com
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society - GlobeNewswire Inc.
No reported rejections followed Eledon’s drug after six months, versus seven for tacrolimus. Phase 3 is expected in Q4 2026. - Stock Titan
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society - FinancialContent
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society - The Manila Times
A treatment to prevent kidney transplant rejection will be presented Sept. 22 - Stock Titan
Eledon submits IND for tegoprubart islet cell transplant study By Investing.com - Investing.com Nigeria
Eledon submits IND for tegoprubart islet cell transplant study By Investing.com - Investing.com Australia
Eledon submits IND for tegoprubart islet cell transplant study By Investing.com - Investing.com South Africa
Eledon Pharmaceuticals Submits IND Application to US FDA for Tegoprubart - marketscreener.com
Eledon submits IND for tegoprubart islet cell transplant study - investing.com
Eledon submits IND for tegoprubart islet cell transplant study By Investing.com - Investing.com Canada
Eledon submits IND for tegoprubart islet cell transplant study By Investing.com - Investing.com UK
12 people with type 1 diabetes no longer needed insulin after transplants. Three more are joining. - Stock Titan
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026 - manilatimes.net
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026 - The Manila Times
Eledon Pharmaceuticals (ELDN) Slips 3.6% to $3.2, Holding Between Support and ResistanceNAAIM Leverage - dars.gov.et
Eledon Pharmaceuticals (ELDN) Slips 3.6% to $3.2, Holding Between Support and ResistanceVolatility Smile - dars.gov.et
Eledon Pharmaceuticals (ELDN) Retreats 3.6% to $3.2 Amid Biotech Selling PressureMerger Arbitrage - vinanet.vn
Eledon Pharmaceuticals (ELDN) Retreats 3.6% to $3.2 Amid Biotech Selling PressureETF Flow - dars.gov.et
Eledon Pharmaceuticals (NASDAQ:ELDN) Upgraded at Wall Street Zen - MarketBeat
Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Eledon Pharmaceuticals (ELDN) Slips 1.86% as Shares Test Key Support at $3.52Breakout Confirmation - vinanet.vn
Eledon Pharmaceuticals (ELDN) Slips 1.86% as Shares Test Key Support at $3.52Fast Moving Stocks - dars.gov.et
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
Eledon Pharmaceuticals (NASDAQ:ELDN) Posts Quarterly Earnings Results, Misses Expectations By $0.11 EPS - MarketBeat
Eledon Pharmaceuticals Reports Q2 2026 Form 10-Q Highlighting Going Concern and Funding Challenges - Kalkine Media
Form 8K Eledon Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Nigeria
Eledon Pharmaceuticals (ELDN) - Zacks Investment Research
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Eledon Q2 EPS misses estimates as net loss widens 182% YoY - scanx.trade
Form 8K Eledon Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Canada
Form 8K Eledon Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com India
Form 8K Eledon Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com UK
Eledon Pharmaceuticals (ELDN) widens Q2 loss while advancing tegoprubart to Phase 3 - Stock Titan
Eledon Islet Study: All 12 Patients Reached Insulin Independence - Stock Titan
ELDN Q1 2026 Earnings: Wider-than-Expected Loss Meets Mild Share UptickInterim Report - vinanet.vn
Eledon Pharmaceuticals (ELDN) Holds Above $3.60 Support After Modest AdvanceAnchored VWAP - vinanet.vn
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewswire
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Yahoo Finance
ELDN Q1 2026 Earnings: Wider-than-Expected Loss Pressures SharesLong-Term Guidance - vinanet.vn
Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Eledon Pharmaceuticals (ELDN) Institutional Ownership 2026 - MarketBeat
Eledon Pharmaceuticals (ELDN) Expected to Release Quarterly Earnings on Thursday - MarketBeat
Eledon Pharmaceuticals (ELDN) Gains 2.19% as Shares Trade Between Key LevelsFloat Adjusted Cap - dars.gov.et
Eledon Pharmaceuticals Inc. (ELDN) Q1 2026 Earnings: EPS Misses Estimates by 77.23% as Stock DeclinesRevenue Guidance Update - vinanet.vn
Vanguard Capital Management (ELDN) discloses 5.05% passive stake in Eledon Pharmaceuticals - Stock Titan
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Eledon Pharmaceuticals Inc Azioni (ELDN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Eledon Pharmaceuticals Inc Azioni (ELDN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hillson Jan | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
3,430 |
0 |
3,430 |
| Kirk Allan | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
3,430 |
0 |
3,430 |
| Katkin Keith | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
8,575 |
0 |
8,575 |
| Lee June | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
3,430 |
0 |
3,430 |
| Robinson James A. Jr. | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
3,430 |
0 |
3,430 |
1.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):